May 30, 2008
Hotel Concorde La Fayette
Paris, France
Update on Quantitative Approaches for Predicting First-in-Man (FIM) Dosing Regimens
Jonathan K. Wagg, M.D., Ph.D., Senior Scientist, Pharsight
View Presentation (sign-in required)
®
PK-PD Modeling and Simulation at Organon, a Part of Schering-Plough Corporation - M&S Imbedded in Drug Development
Thomas Kerbusch, Ph.D., PK-PD Section Head, N.V. Organon
(posted with kind permission of N.V. Organon, Oss, Netherlands)
View Presentation (sign-in required)
Modeling and Simulation Using Public-Domain Metadata: An Illustration with a Rheumatoid Arthritis Data Set
Klaas Prins, Ph.D., Senior Scientist, Pharsight
View Presentation (sign-in required) ![]()
Modeling and Simulation to Support Clinical Drug Development in Oncology
Rene Bruno , Ph.D., Managing Director, Pharsight
View Presentation (sign-in required)
Modeling and Simulation of DEBIO-025 to Support Design of a Dose-Response Monotherapy Study in HIV-1 Infected Patients
Klaas Prins, Ph.D., Senior Scientist, Pharsight
(posted with kind permission of Debiopharm SA, Lausanne, Switzerland)
View Presentation (sign-in required)